Phase II Trial of Hihg-Dose Thiotepa, Busulfan, Cyclophosphamide, and Rituximab With Autologous Stem Cell Transplantation for Patients With CNS Involvement by Non-Hodgkin's Lymphoma or Primary CNS Lymphoma.

Trial Profile

Phase II Trial of Hihg-Dose Thiotepa, Busulfan, Cyclophosphamide, and Rituximab With Autologous Stem Cell Transplantation for Patients With CNS Involvement by Non-Hodgkin's Lymphoma or Primary CNS Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Rituximab (Primary) ; Busulfan; Cyclophosphamide; Thiotepa
  • Indications CNS cancer; Lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 14 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016, according to ClinicalTrials.gov record.
    • 27 Jul 2015 According to the the ClinicalTrials.gov record, planned end date changed from 1 Mar 2015 to 1 Dec 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top